STAAR Surgical (STAA) Q2 Revenue Tops 9%

STAAR Surgical reported Q2 FY2025 GAAP revenue of $44.3 million and an EPS loss of $(0.34), both exceeding analyst expectations, driven by robust 10% year-over-year sales growth outside China that largely offset a sharp decline in Chinese revenue. However, total revenue still fell 55.2% year-over-year, and management withdrew its full-year 2025 financial guidance, citing persistent uncertainties in China and tariff risks. The company expects China sales to normalize in Q3 FY2025 and is implementing restructuring and leveraging its new Switzerland facility to mitigate future tariff exposure, signaling a focus on operational efficiency amidst market volatility.

Analysis

STAAR Surgical's Q2 FY2025 results present a mixed operational picture, characterized by a significant beat against analyst estimates but a severe contraction in year-over-year performance. The company reported GAAP revenue of $44.3 million, surpassing consensus by 9.4%, and a narrower-than-expected EPS loss of $(0.34). This outperformance was driven by a robust 10% year-over-year increase in net sales excluding China, indicating strong underlying demand in other global markets. However, these results are overshadowed by a 55.2% YoY drop in total revenue and a swing from a $0.15 profit per share in the prior year, primarily due to a sharp decline in China from distributor inventory destocking. In response to the challenging environment, management has withdrawn its FY2025 financial guidance, citing ongoing uncertainty in China and unresolved tariff risks. Operationally, the company is implementing cost controls to reduce its SG&A run rate and is strategically ramping up its new Switzerland facility to mitigate future tariff exposure on China-bound products, though this is currently pressuring gross margins, which fell to 74.0% from 79.2% a year ago. While management anticipates a normalization of China sales in Q3 and has a potential growth catalyst in the pending approval of its EVO+ lens, the withdrawal of guidance introduces significant near-term uncertainty for investors.

Key Decisions for Investors

• Investors should weigh the positive signal of 10% sales growth outside of China against the significant risks posed by the withdrawal of full-year guidance and the 55.2% year-over-year revenue collapse.
• The primary near-term catalyst to monitor is the expected normalization of sales in China during Q3; any deviation from this recovery timeline could significantly impact the stock's performance.
• Consider the stock's defensive measures, such as the new Switzerland facility and cost-cutting initiatives, but remain cautious due to continued gross margin pressure and the declining cash position, which fell from $222.8 million to $189.9 million in the quarter.
• Long-term growth prospects hinge on catalysts like the regulatory approval of the new EVO+ lens in China, making any news on this front a key indicator for the company's future trajectory.